# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price ...
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which beat the analyst consensus estimate of $(...
Piper Sandler analyst Joseph Catanzaro maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and maintains $105 price...
Truist Securities analyst Srikripa Devarakonda reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 pri...
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price ...
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(...
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23...
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdin...